Skip to main content

Day: June 26, 2023

Intermap Announces Subscription with Outdoor Recreation Platform

Integration of high-resolution elevation data enhances outdoor mapping experience DENVER, June 26, 2023 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced a two-year data subscription agreement with a leading outdoor recreation and fitness platform. Intermap’s NEXTMap® elevation data is seamlessly integrated into the platform, providing users with access to precise terrain information for planning routes, collecting performance metrics and exploring trails and points of interest. The Company’s datasets provide a comprehensive solution for global elevation data, ensuring continuous, consistent data quality worldwide. The platform has tens of millions of active users who will benefit from NEXTMap’s detailed...

Continue reading

Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report initial clinical data for FLT201 in third quarter of 2023 Parkinson’s disease program leverages same longer-acting GCase enzyme as FLT201, with aim of developing a gene therapy for genetically defined patient subset with GBA1 mutations LONDON, June 26, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the Phase 1/2 GALILEO-1 clinical trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease type 1. Gaucher disease is a debilitating genetic disorder in which a deficiency of the GCase enzyme leads to a buildup of fatty...

Continue reading

CVG Added to Membership of the Russell 2000® Index

NEW ALBANY, Ohio, June 26, 2023 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI), a diversified industrial products and services company, was added to membership of the US small-cap Russell 2000® Index as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000® Index is effective after the US market opens on June 26, 2023 and remains in place for one year. The stock was also automatically added to the appropriate growth and value indexes. “We are pleased to have been added as a member of the U.S. small-cap Russell 2000® Index, one of the most widely cited performance benchmarks for emerging U.S. companies,” commented Andy Cheung, Chief Financial Officer. “As we continue to focus on strategy execution and operational excellence, we look forward to expanding our reach within the investment community.” About CVG At CVG,...

Continue reading

Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226). Different types of drug addiction fall under the umbrella term of substance use disorders or SUD. Physicians have a better understanding of SUD and given recent research findings we now know that these conditions are treatable with effective medical interventions.1 “Our mission at Adamis Pharmaceuticals is to become the market leader on interventions...

Continue reading

Enovix Announces Appointment of Joseph Malchow and Bernard Gutmann to Its Board of Directors

Joe Malchow Joe Malchow joins Enovix Board of DirectorsBernard Gutmann Bernard Gutmann joins Enovix Board of DirectorsFREMONT, Calif., June 26, 2023 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced the appointment of Joseph Malchow, founding partner at HNVR Technology Investment Management and board member at Enphase Energy, Inc., and Bernard Gutmann, a 40-year semiconductor industry veteran and former CFO at On Semiconductor, to its Board of Directors (the “Board”) effective June 22, 2023. These appointments expand the Board to eight directors, six of whom are independent. “I am committed to the operational success of Enovix and the addition of Joe and Bernard enhances our Board’s skillset and demonstrates our commitment to drive long-term value to our...

Continue reading

Dragonfly Energy Joins the Russell 2000® Index

RENO, Nev., June 26, 2023 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and producer of deep cycle lithium-ion storage batteries, today announced it has joined the Russell 2000® Index. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. “The Russell indices set the bar for global...

Continue reading

Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform

Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise MORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with uMotif, a clinical trial technology company putting the patient at the center of research. The collaboration will help accelerate clinical trials and bring new therapies to patients faster through a more efficient, end-to-end digital platform that includes robust Electronic Clinical Outcome Assessment (eCOA) and Electronic Patient-reported Outcomes (ePRO) capabilities. In addition to uMotif providing eCOA and ePRO services for Syneos Health customers, the companies will develop and deploy an exclusive patient-centric platform to deliver...

Continue reading

NFI provides timing update on its comprehensive refinancing plan and schedules second quarter 2023 financial results and conference call for August 2, 2023

All amounts shown in this press release are in U.S. dollars unless otherwise indicated. WINNIPEG, Manitoba, June 26, 2023 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB, TSX: NFI.R) NFI Group Inc. (the “Company”), a leader in zero-emission electric mobility solutions, today provided an update on the expected timing to complete its previously announced comprehensive refinancing plan (the “Refinancing Plan”). NFI expects to concurrently complete all elements of its Refinancing Plan prior to the release of its second quarter financial results on Wednesday, August 2, 2023. To support this expected timing, NFI has received an extension of the date for the completion of the required amendments and the financial covenant waivers under the Company’s existing North American senior secured credit facility (the “North American Facility”)...

Continue reading

Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions

In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months. Following islet transplants to the 8-channel Cell Pouches, patients in the first cohort required only modest islet top-up via portal vein to achieve insulin independence, supporting the contribution to blood glucose control from islet grafts in the Cell Pouch™. Five of the 7 planned patients have been enrolled in the second cohort and implanted with higher capacity 10-channel Cell Pouches. Three patients in the second cohort have received their first pancreatic islet transplant to Cell Pouch. Persistent fasting and stimulated serum C-peptide confirms stable islet graft function in the first evaluable patient to receive islet transplants...

Continue reading

Interfield Global Software Inc. Signs AARO to Co-Marketing Agreement

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) — Interfield Global Software Inc. (NEO: IFSS) (the “Company”) is pleased to announce that Interfield Software Solutions LLC, the Software as a Service division of the Company (“Interfield”), has signed a co-marketing agreement with AARO Middle East DMCC (“AARO”). AARO is part of AARO Systems AB Sweden and is in the business of accounting software services, executive recruitment and event management. In furtherance of the agreement, Interfield will be a partner of the 2023 Finex Summit, a global virtual summit on September 13, 2023 targeted at the continuing personal development of Global Finance Leaders. This annual summit is managed by AARO Middle East and CFO University (www.finexsummit.com). For over 30 years, AARO been implementing technology-based accounting...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.